GE VernovavsStrata Critical Medical

GEV and SRTA stock compared: price, dividend, valuation and results, from SEC filings.

GEV

GE Vernova Inc.

$763.57

Value $206B

-4.93%
GEV's page

SRTA

Strata Critical Medical, Inc.

$5.42

Value $471M

-1.63%
SRTA's page

GE Vernova (GEV) has a market value of $206B and Strata Critical Medical (SRTA) $471M. Over the last year, with dividends, GEV moved +32.4% and SRTA +13.2%. Dividend yield: GEV 0.26%, SRTA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    GEV$206B

    SRTA$471M

    GEV is 437 times SRTA

  • Revenue, 12 months

    GEV$44.0B

    SRTA$281M

    GEV is 157 times SRTA

  • Net income, 12 months

    GEV$10.4B

    SRTA-$25M

  • Operating margin

    GEV6.4%

    SRTA-6.6%

    13.0 points apart

  • ROIC

    GEV19.5%

    SRTA-5.2%

    24.7 points apart

  • P/E

    GEV19.9

    SRTA–

  • Dividend yield

    GEV0.3%

    SRTA0.0%

    0.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

GEV+32.4%

SRTA+13.2%

100150200DecFebAprJunAugOct
Returns by period
PeriodGEVWith dividendsSRTAWith dividends
1 year since November 14, 2025+32.4%Price +32.0%+13.2%Price +13.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

GEVGE VernovaSRTAStrata Critical Medical

Valuation

GEVSRTA
Valuation
Price$763.57$5.42
Market value$206B$471M
Enterprise value (EV)$192B$430M
P/E19.9–
P/E, 5-year median––
P/B18.11.7
EV/EBIT67.9–
Free cash flow yield8.3%0.2%

Results and growth

GEVSRTA
Results and growth
Revenue, 12 months$44.0B$281M
Net income, 12 months$10.4B-$25M
Free cash flow, 12 months$17.1B$806.0K
Earnings per share, 12 months$38.00-$0.30
Revenue growth, year on year9.0%34.3%
Revenue growth a year, past+8.7%over 3 years+53.1%over 5 years
EPS growth a year, past––

Margins and returns on capital

GEVSRTA
Margins and returns on capital
Gross margin21.7%21.6%
Operating margin6.4%-6.6%
Net margin23.5%-8.8%
ROIC19.5%-5.2%
ROE90.8%-8.8%

Balance sheet

GEVSRTA
Balance sheet
Cash$16.8B$42M
Total debt$3.7B$3.6M
Net debt / EBITDA-4.1–
Interest cover––

Dividends and buybacks

GEVSRTA
Dividends and buybacks
Dividend yield0.3%–
Dividend per share, 12 months$2.00–
Dividend growth a year, past––
Buyback yield1.6%–
Shareholder yield1.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: GEV or SRTA

Didn't find what you were looking for?

Ask us
Which is bigger, GE Vernova or Strata Critical Medical?

By market value, GE Vernova ($206B) is about 436.5 times Strata Critical Medical ($471M), at today's prices.

How did GEV and SRTA stock do over the last 1 years?

Since November 14, 2025, GEV's price moved +32.0% and SRTA's +13.2%. With dividends: GEV +32.4% (+32.4% a year), SRTA +13.2% (+13.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, GEV or SRTA?

The dividend yield at today's price is 0.26% for GE Vernova and none for Strata Critical Medical. Over the last twelve months they paid $2.00 and – per share.

Which has the higher profit margins, GE Vernova or Strata Critical Medical?

Over the last twelve months, the net margin was 23.5% for GE Vernova and -8.8% for Strata Critical Medical, and the operating margin 6.4% and -6.6%. Revenue was $44.0B and $281M.

Which is the better investment, GE Vernova or Strata Critical Medical?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.